Nasdaq:BIAF
bioAffinity Technologies, Inc.
A pre-revenue biotech firm generating $9.4M in annual revenue while investing heavily in oncology and infectious disease research tools.
Key Metrics
Investment Thesis
Bull Case
BIAF possesses unique proprietary technology with high gross margins that could generate significant revenue if licensed or commercialized successfully. The company's focus on unmet needs in oncology and infectious diseases positions it well for strategic partnerships that can fund operations without immediate dilution. Recent revenue growth from $0M in 2022 to $9.4M in 2024 demonstrates emerging market traction.
Bear Case
The company is burning through cash at a rapid pace with a negative operating cash flow of $7.3M and a massive retained earnings deficit of $53.6M. Operating expenses nearly double the revenue, creating an unsustainable financial trajectory without immediate major financing or acquisitions. The high risk profile of biotech startups combined with limited current profitability makes capital preservation difficult for existing shareholders.
About bioAffinity Technologies, Inc.
BioAffinity Technologies Inc. (BIAF) is a biotechnology company focused on developing proprietary reagents and therapeutic candidates for oncology and infectious diseases. The firm primarily serves the pharmaceutical industry by providing critical research tools and potential drug assets to accelerate partner pipelines. With recent annual revenue of $9.4M, the company balances its high-cost R&D operations with strategic financing activities to fund growth.
Analysis
Management Discussion
The company reported a net loss of $9.0M driven by substantial general and administrative expenses of $9.9M and operating expenses totaling $18.3M against $9.4M in revenue. Cash flow from operations was negative at $7.3M, though cash flow from financing provided $5.6M to support liquidity needs. Despite the loss, gross profit remained positive at $9.4M due to high-margin reagent sales.
Industry Overview
The biotechnology sector is characterized by high R&D costs and long development timelines, but offers significant upside potential through breakthrough therapies and diagnostic tools. Companies like BIAF play a critical role in the upstream research space by supplying essential reagents that enable drug discovery and clinical trial success. Success in this industry often hinges on securing strategic partnerships with large pharma companies to offset the high cost of goods sold and administrative overhead.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $4.8K | $7.9M | $9.4M |
| Cost of Revenue | $467 | $0 | $0 |
| Gross Profit | $4.3K | $7.9M | $9.4M |
| Operating Expenses | $4.0M | $15.9M | $18.3M |
| Operating Income | $-4.0M | $-8.0M | $-9.0M |
| R&D | $1.1M | $1.5M | $1.5M |
| G&A | $2.7M | $6.8M | $9.9M |
| Stock-Based Comp | $248.6K | $748.8K | $989.7K |
| D&A | $10.2K | $249.6K | $605.6K |
| Depreciation | — | $233.1K | $162.3K |
| Amortization | — | $16.5K | $58.3K |
| Other OpEx | $145.5K | $7.6M | $6.9M |
| Non-Operating Income | $-4.1M | $57.2K | $-74.7K |
| Interest Expense | $2.5M | $37.1K | — |
| Interest Income | $46.7K | $122.1K | $17.6K |
| Pre-Tax Income | $-8.2M | $-7.9M | $-9.0M |
| Income Tax | $2.5K | $21.0K | $11.7K |
| Continuing Ops | $-8.2M | $-7.9M | $-9.0M |
| Discontinued Ops | $0 | $16.5M | $0 |
| Net Income | $-8.2M | $8.6M | $-9.0M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-8.2M | $8.6M | $-9.0M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $12.0M | $4.0M | $2.7M |
| Cash & Equivalents | $11.4M | $2.8M | $1.1M |
| Inventory | $5.5K | $18.5K | $27.6K |
| Prepaid Expenses | $531.9K | $321.0K | $423.0K |
| Other Current Assets | $10.5K | $811.7K | $1.1M |
| Long-Term Assets | $220.4K | $4.2M | $3.8M |
| PP&E (Net) | $214.4K | $458.6K | $375.4K |
| Intangibles | — | $833.5K | $775.1K |
| Goodwill | — | $1.4M | $1.4M |
| Operating Leases | — | $370.3K | $463.0K |
| Other LT Assets | $6.0K | $1.2M | $800.5K |
| Total Assets | $12.2M | $8.2M | $6.5M |
| Current Liabilities | $1.1M | $2.2M | $3.1M |
| Accounts Payable | $345.0K | $604.8K | $987.3K |
| Current Leases | — | $94.7K | $127.5K |
| Other Current Liab | $251.7K | $398.5K | $591.4K |
| Long-Term Liabilities | $0 | $1.1M | $806.7K |
| LT Operating Leases | — | $283.0K | $342.1K |
| Other LT Liab | — | $835.5K | $464.6K |
| Total Liabilities | $1.1M | $3.4M | $3.9M |
| Shareholders' Equity | $11.0M | $4.9M | $2.6M |
| Paid-In Capital | $47.7M | $49.4M | $56.1M |
| Retained Earnings | $-36.7M | $-44.6M | $-53.6M |
| Total L&E | $12.2M | $8.2M | $6.5M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-8.2M | $8.6M | $-9.0M |
| Non-Cash Adjustments | $3.0M | $-14.5M | $710.0K |
| Working Capital Changes | $1.1M | $-132.3K | $1.1M |
| Cash from Operations | $-4.1M | $-6.0M | $-7.3M |
| Capital Expenditures | $220.0K | $22.9K | $79.1K |
| Cash from Investing | $-220.0K | $-2.2M | $-79.1K |
| Cash from Financing | $14.3M | $-345.0K | $5.6M |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $10.1M | $-8.6M | $-1.7M |
| Beginning Cash | $1.4M | $11.4M | $2.8M |
| Ending Cash | $11.4M | $2.8M | $1.1M |
Frequently Asked Questions
How does bioAffinity Technologies, Inc. make money?
1) Proprietary Reagents and Research Tools for Oncology and Infectious Diseases, 2) Therapeutic Development Programs targeting cancer and viral infections, 3) Strategic Licensing Partnerships with Pharmaceutical Entities
What are the main risks for BIAF?
Significant negative net loss of $9.0M indicating high burn rate and reliance on external capital, Limited revenue base of only $9.4M compared to operating expenses of $18.3M creating cash flow pressure, Potential dilution from equity financing given the retained earnings deficit of $53.6M, Regulatory uncertainties in bringing novel therapeutics to market.
What is BIAF's competitive advantage?
Proprietary reagent platforms that offer unique specificity for difficult-to-target biological markers, Strong partnerships with major pharmaceutical companies providing steady cash flow to offset R&D burn, Highly specialized scientific team with deep expertise in complex disease mechanisms.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.